JMP Securities Reaffirms “Market Outperform” Rating for Blueprint Medicines (NASDAQ:BPMC)
JMP Securities reiterated their market outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report issued on Friday morning,Benzinga reports. They currently have a $125.00 price objective on the biotechnology company’s stock. Several other analysts have also recently issued reports on BPMC. UBS Group started coverage on Blueprint Medicines in a […]
JMP Securities reiterated their market outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report issued on Friday morning,Benzinga reports. They currently have a $125.00 price objective on the biotechnology company’s stock. Several other analysts have also recently issued reports on BPMC. UBS Group started coverage on Blueprint Medicines in a […]
